start-ver=1.4 cd-journal=joma no-vol=64 cd-vols= no-issue=1 article-no= start-page=19 end-page=26 dt-received= dt-revised= dt-accepted= dt-pub-year=2010 dt-pub=201002 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Irinotecan Hydrochloride (CPT-11) in Dialysis Patients with Gastrointestinal Cancer en-subtitle= kn-subtitle= en-abstract= kn-abstract=

We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis patients with gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such patients. For comparison, the same parameters were also investigated in 10 cancer patients not undergoing dialysis. Items investigated included (1) plasma concentrations of SN-38, SN-38G and CPT-11 at 0, 1, 12, 24, 36, 48 and 72h after administration, together with a comparison of mean AUC values for 3 dose levels of CPT-11 (50, 60 and 70mg/m2) in dialysis patients and controls;and (2) occurrence of adverse events. Several findings emerged from this study:(1) No significant difference was observed in the AUC for SN-38 or CPT-11 between the dialysis and control groups;(2) The AUC for SN-38G at each dose was significantly higher in dialysis patients;and (3) Grade 1-4 leucopenia was observed in 11 of the dialysis patients. One patient developed grade 4 leucopenia and died due to sepsis. Anorexia, diarrhea, nausea, alopecia and interstitial pneumonia occurred in 6 dialysis patients. We found changes in drug dispositions of CPT-11, SN-38 and SN-38G in dialysis patients, suggesting that hepatic excretion, especially that of SN-38G, was increased. No significant difference in occurrence of adverse events was observed between the 2 groups. This indicates that CPT-11 can be administered safely in patients on dialysis.

en-copyright= kn-copyright= en-aut-name=AshizawaTatsuto en-aut-sei=Ashizawa en-aut-mei=Tatsuto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=IwahoriTohru en-aut-sei=Iwahori en-aut-mei=Tohru kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=YokoyamaTakayoshi en-aut-sei=Yokoyama en-aut-mei=Takayoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=KiharaYuu en-aut-sei=Kihara en-aut-mei=Yuu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KonnnoOsamu en-aut-sei=Konnno en-aut-mei=Osamu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=JyojimaYoshimaro en-aut-sei=Jyojima en-aut-mei=Yoshimaro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=AkashiIsao en-aut-sei=Akashi en-aut-mei=Isao kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=NakamuraYuuki en-aut-sei=Nakamura en-aut-mei=Yuuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=HamaKouichirou en-aut-sei=Hama en-aut-mei=Kouichirou kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=IwamotoHitoshi en-aut-sei=Iwamoto en-aut-mei=Hitoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=SegawaMai en-aut-sei=Segawa en-aut-mei=Mai kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=TakeuchiHironori en-aut-sei=Takeuchi en-aut-mei=Hironori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=HiranoToshihiko en-aut-sei=Hirano en-aut-mei=Toshihiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=NagaoTakeshi en-aut-sei=Nagao en-aut-mei=Takeshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= affil-num=1 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=2 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=3 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=4 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=5 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=6 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=7 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=8 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=9 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=10 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=11 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University affil-num=12 en-affil= kn-affil=Department of Practical Pharmacy, Tokyo University of Medical University Pharmacy and Life Science affil-num=13 en-affil= kn-affil=Department of Clinical Pharmacology, Tokyo University of Medical University Pharmacy and Life Science affil-num=14 en-affil= kn-affil=Department of Surgery, Hachioji Medical Center of Tokyo Medical University en-keyword=irinotecan hydrochloride (CPT-11) kn-keyword=irinotecan hydrochloride (CPT-11) en-keyword=chronic kidney disease (CKD) kn-keyword=chronic kidney disease (CKD) en-keyword=end-stage renal disease (ESRD) kn-keyword=end-stage renal disease (ESRD) en-keyword=dialysis kn-keyword=dialysis en-keyword=colorectal cancer kn-keyword=colorectal cancer END